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Review

Evidence supporting idarucizumab for the reversal of dabigatran☆,☆☆,★
Charles V. Pollack Jr, MA, MD ⁎
Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA

a r t i c l e

i n f o

a b s t r a c t
Idarucizumab is a monoclonal antibody fragment speciﬁcally targeted to dabigatran. It has demonstrated prompt
and durable reversal of the anticoagulant effects of dabigatran in animal studies and phase 1 studies of young, elderly, and renally impaired volunteers. Although elective invasive procedures and most bleeding complications
in dabigatran-treated patients can be managed by temporarily stopping dabigatran therapy and using supportive
measures, there are rare clinical situations that require urgent reversal of the anticoagulant effect of dabigatran.
The effectiveness and safety of 5 g of intravenous idarucizumab is being investigated in a prospective, open-label,
single-cohort study in patients with serious bleeding or in those requiring an urgent procedure. In an interim
analysis of the ﬁrst 90 participants, idarucizumab rapidly and completely reversed the anticoagulant activity of
dabigatran in 88%-98% of participants, and there were no safety concerns, with no deaths or serious adverse
events being attributable to idarucizumab. Supported by these interim results, idarucizumab has been approved
in the United States and the European Union for use when reversal of the anticoagulant effects of dabigatran is
needed for emergency surgery/urgent procedures or in patients with life-threatening or uncontrolled bleeding.
Clinical use of idarucizumab should follow the same processes as patient enrollment in this study, which is
projected to be completed in 2016. The outcomes achieved with this speciﬁc reversal agent are likely to be of continued interest to treating physicians.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

Dabigatran is a direct oral anticoagulant (DOAC) that inhibits the
function of thrombin without dependence on vitamin K antagonism
[1]. In the penultimate step of the normal coagulation cascade, thrombin
catalyzes the conversion of ﬁbrinogen to ﬁbrin, resulting in clot stabilization. Patients treated with dabigatran have normal synthesis and
levels of thrombin, but competitive inhibition of thrombin activity by
dabigatran effectively prevents completion of the coagulation process.
This mechanism of action has been harnessed to provide effective
anticoagulation in patients with nonvalvular atrial ﬁbrillation (NVAF)
to reduce the risk of ischemic stroke and systemic embolization, and
in patients with or at risk of venous thromboembolic disease [1].
In clinical trials, dabigatran has been associated with similar or reduced
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rates of the key safety end points of major and intracranial bleeding, depending on the dose and the indication, as well as similar rates of fatal
bleeding compared with vitamin K antagonists (VKAs), such as warfarin
[2-4]. Nonetheless, some risk of bleeding unavoidably accompanies the
decision to use an anticoagulant in a patient, especially older patients
with the comorbidities that typically accompany NVAF. Most bleeding
complications associated with the use of dabigatran are minor or at
worst moderate in severity and can be managed by simply temporarily
withholding the drug and supporting the patient with general physical
or pharmacologic hemostatic measures, replacement of shed blood, and
observation [5,6]. The short half-life of dabigatran relative to VKAs,
which inhibit the synthesis of multiple coagulation factors over days,
is an important consideration in these strategies [1,7]. Typically, the effect of dabigatran–in the absence of acute renal failure or acute
overdose–dissipates within 12 hours of a 150-mg dose, with steadystate dabigatran plasma concentrations decreasing to b100 ng/mL and
activated partial thromboplastin time to approximately 1.5 times baseline levels in that interval [8,9].
Similarly, the short half-life of dabigatran facilitates the timing of
elective invasive procedures. Withholding the drug for 1-5 days, depending on renal status and the magnitude of the bleeding risk associated with the procedure, allows the intervention to be accomplished with
restored hemostasis [1]. Because the onset of action of dabigatran is–like
its offset–rapid [10], re-initiation of anticoagulation can generally be accomplished as soon as postprocedural hemostasis is restored.
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In rare clinical situations, these general measures are insufﬁcient to
address bleeding complications or bleeding concerns in patients requiring emergent invasive procedures in the context of anticoagulation with
dabigatran. In cases of uncontrolled or life-threatening hemorrhage or
when an invasive procedure cannot be delayed long enough for natural
decay of the anticoagulant effect of dabigatran, more deﬁnitive reversal
of anticoagulation is desirable. If dabigatran was ingested within the
preceding 2-3 hours, oral administration of activated charcoal may
limit absorption of the most recent dose [8,11,12]. Elimination of
dabigatran–which is 80% renal–can be maintained by vigorous ﬂuid administration and resulting diuresis [1,5,8]. However, these approaches
are of limited impact in most emergency situations. Unlike the other
DOACs, dabigatran can be removed rather effectively from the circulation by hemodialysis, although data supporting this approach are limited [1,13,14]. Unfortunately, this is a cumbersome and logistically
challenging approach in the emergency situation, in patients without
established dialysis access.
Such patients, therefore, require urgent reversal of the anticoagulant
effect of dabigatran (ie, normalization of thrombin activity in the presence of an effective antithrombin agent). It is not possible to administer
pure thrombin to patients to overcome the competitive blockade of
dabigatran. Exogenous thrombin can be given in combination with
other coagulation factors using fresh frozen plasma or 3- or 4-factor prothrombin complex concentrates [12]. However, because levels of
thrombin and other coagulation factors are presumably normal in
dabigatrantreated patients, this approach introduces a concern for iatrogenic creation of a hypercoagulable or prothrombotic state, as has been
demonstrated in an animal study [15], potentially trading one worrisome situation for another.
The preferred approach in such situations, therefore, would be to use
a speciﬁc reversal agent to remove the anticoagulant effect of
dabigatran, disinhibiting native thrombin and returning the patient to
his or her baseline coagulation status. An ideal reversal agent would
be speciﬁc to the administered anticoagulant, engage in no other
drugedrug interactions, have no inherent pro- or anticoagulant effect,
have rapid and predictable onset of action, be readily prepared and administered, and be dosed in a simple fashion. Additionally, it should
have a sufﬁciently durable effect that in cases of bleeding, coagulation
can be maintained while deﬁnitive source management is being accomplished, and in preprocedural patients, the procedure can be completed
without the additional bleeding risk wrought by anticoagulation.
Idarucizumab meets these criteria for patients treated with dabigatran
who require immediate anticoagulation reversal [16]. Idarucizumab is a
humanized monoclonal antibody fragment speciﬁcally directed at
dabigatran [17]. The active site of idarucizumab is structurally similar to
the dabigatran binding site of thrombin, although the antibody lacks enzymatic activity. Idarucizumab binds dabigatran with approximately
350 times the avidity with which thrombin binds dabigatran. As such,
in sufﬁcient doses, idarucizumab readily displaces dabigatran from
thrombin and tightly binds it, thereby allowing ﬁbrin formation to
ensue normally. The antibody can bind free and thrombinbound
dabigatran, as well as extravascular dabigatran, as it enters the central
compartment after changes in the concentration gradient [18], thus
preventing the anticoagulant from the periphery from subsequent binding to thrombin.
The interaction between idarucizumab and dabigatran is characterized by an extraordinarily rapid on rate (measured in milliseconds)
and a very slow off rate, consistent with the high-afﬁnity binding typical
of an antibodyeantigen bond [17]. Binding is effectively irreversible,
with very little dissociation of the idarucizumabedabigatran complex before renal excretion, even in patients with renal compromise
[16-18]. When infused intravenously, peak plasma concentrations of
idarucizumab are achieved almost immediately, allowing prompt binding to dabigatran [19]. The key clinical ﬁndings from volunteer studies
of idarucizumab are reviewed in detail in the review article by Reilly
et al. within this special issue and are summarized in Table [20].

Table
Key Clinical Phase 1 Findings with Idarucizumab in Healthy Volunteers
Objective

No. of
Findings
Subjects

Reversal of anticoagulant effect of
dabigatran in healthy young
(age 18-64 y) volunteers
Reversal of anticoagulant effect of
dabigatran in elderly
(age 65-80 y) volunteers
Reversal of anticoagulant effect of
dabigatran in subjects with
creatinine clearance 44–79
mL/min
Pharmacokinetics of
idarucizumab alone in healthy
volunteers
Pharmacokinetics of dabigatran in
volunteers given idarucizumab

59

Dose-dependent decrease in ECT,
dTT, aPTT, TT, and ACT

16

Dose-dependent decrease in ECT,
dTT, aPTT, TT, and ACT

18

Dose-dependent decrease in ECT,
dTT, aPTT, TT, and ACT

110

Initial t1/2 ~45 minutes

93

Unbound dabigatran concentrations
determined using HPLC/MS parallel
results of clotting tests
Full anticoagulant effect of
dabigatran 24 h after idarucizumab
administration
No hypersensitivity, 1 subject
developed new anti-drug antibodies
No increase in thrombin generation
compared with placebo

Re-initiation of dabigatran 24 h
after idarucizumab
administration
Re-exposure to idarucizumab 2
mo after initial administration
Evaluation of potential
procoagulant activity of
idarucizumab
Safety of idarucizumab

12

6
104

203

No dose-related adverse events, no
serious adverse events

See references [19,22].
ACT = activated clotting time; aPTT = activated partial thromboplastin time;
dTT = dilute thrombin time; ECT = ecarin clotting time; HPLC/MS = high-performance
liquid chromatography/tandem mass spectrometry.
Reproduced with permission from Pollack et al. [21]

Animal studies of idarucizumab likewise showed a prompt and durable reversal of the anticoagulant effects of dabigatran, without
prothrombotic effect [17,23]. In addition, phase I studies showed only
a low level of antibody formation after single or repeat exposure to
idarucizumab [16,18,19]. No severe or serious drug-related adverse
events were identiﬁed [16,18,19,22]. The only side effect was a transient, doserelated increase in urinary protein levels, which was to be expected from the excretion of the antigeneantibody complexes via a
saturable renal protein transporter [19].

1. RE-VERSE AD, A Study in Patients
From all indications, then, idarucizumab seemed to be a promising
speciﬁc reversal agent for dabigatran. A clinical study in patients to support registration was developed with input from various regulatory
bodies, and ultimately the following key decisions were made
concerning the design of this study of idarucizumab. An open-label,
single-cohort design was selected. Although it was of course recognized, that a blinded, controlled study would represent better “science,”
this approach was not deemed feasible or appropriate for a study of
idarucizumab. Blinded, placebocontrolled studies had already been conducted in healthy volunteers, demonstrating safety and efﬁcacy according to reversal of clotting tests. The drug seemed to be so effective in
these studies that it was not thought ethical to enroll a placebotreated group. In addition, such a controlled study, with clinical outcomes as the primary end point, would require thousands of patients
and could take 5-10 years to complete owing to the difﬁculties of ﬁnding, consenting, and treating eligible dabigatran-treated patients as
soon as they appeared in emergency departments. Likewise, there
seemed to be no rational comparator control, because there is no standard treatment for dabigatran-associated bleeding, and no studies have
evaluated the effects of other reversal or repletion strategies for
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dabigatran that could represent a “gold standard” alternative to
idarucizumab [21].
Purely clinical inclusion criteria were selected because worldwide
there are no readily available coagulation tests to evaluate the magnitude of dabigatran-associated anticoagulation. Meanwhile, the use of
time-consuming, experimental tests or qualitative tests before enrollment was not deemed to be in the patient’s best interest. The protocol
was instead written to allow full discretion by the local investigator to
make the clinical decision that immediate reversal of anticoagulation
was warranted–whether in the management of hemorrhage or the prevention of procedural bleeding–and that open-label idarucizumab
should be administered [21].
Two groups of dabigatran-treated patients were also selected because oral anticoagulation may occasionally result in 2 separate and distinct clinical challenges: management of hemorrhage abetted by the
iatrogenic coagulopathy (enrolled as “group A”) and management of
anticoagulated patients who are not bleeding but who require urgent
or emergent invasive procedures (“group B”) that [1] cannot be safely
postponed (for at least 8 hours) and [2] cannot be safely performed
without baseline restoration of hemostasis. It was further decided not
to impose clinical limits on the trial population so that it represented
as best as possible the types of patients who would likely be given
idarucizumab in “real-world” situations. The following patients were,
therefore, eligible for inclusion in the trial: those with intracranial hemorrhages, with high expected mortality, those with other lifethreatening conditions (eg, sepsis, multiple trauma with hemorrhagic
shock), and those who had received other reversal/repletion therapies.
In addition, measures to control bleeding in patients in group A were
permitted during the trial. These could include mechanical and supportive measures, decontamination procedures (eg, activated charcoal or dialysis), factor repletion, or the administration of other hemostatic
agents (eg, tranexamic acid) [21].
The primary efﬁcacy end point for the study was based on laboratory
assessments of coagulation, not clinical outcomes. The types of patients
represented in the 2 study groups–bleeding and preprocedural–are
quite heterogeneous in terms of presentation, source of bleeding or
type of procedure needed, comorbidity burden, age, and indication for
anticoagulation. Therefore, meaningful clinical end points could not be
used to establish a sample size for the study. Additionally, idarucizumab
is a speciﬁc reversal agent; that is, it is to be used when reversal of
dabigatranassociated anticoagulation is deemed clinically necessary.
However, successful reversal of anticoagulation in a hemorrhaging patient does not necessarily result in cessation of bleeding. Therefore,
the best measure of reversal is the central laboratory assessment of coagulation parameters known to correlate with dabigatran concentrations. In fact, 2 coagulation assays–the dilute thrombin time (dTT) and
the ecarin clotting time (ECT) can be used in this way [10,24]. Therefore,
although numerous clinical outcomes were to be collected and reported
in the study, the primary end point would be coagulation testing performed by a central laboratory that was geographically and temporally
separated from patient care. These tests were supplemented by also directly measuring the amount of total and unbound dabigatran as a secondary end point, to conﬁrm that the effects on clotting tests reﬂected
the binding/elimination of dabigatran and were not artifacts of the patients’ conditions.
The resulting “real-world” evaluation of idarucizumab was called
the study of the REVERSal Effects of Idarucizumab in Patients on Active
Dabigatran (RE-VERSE AD) and is an ongoing, global, phase 3 prospective, single-cohort study aimed at investigating idarucizumab in
dabigatran-treated patients who present with uncontrollable or lifethreatening bleeding, and in those requiring urgent surgery or intervention [25]. The study is being pursued in more than 400 sites in nearly 40
countries and ultimately will enroll 500 patients. The originally planned
sample size of 200-300 patients was increased to 500 as part of
postapproval requirements by the U.S. Food and Drug Administration
(FDA) [25,26].
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The ﬁrst patient was enrolled in June 2014, and interim results from
the ﬁrst 90 enrollees were presented at the International Society of
Thrombosis and Haemostasis congress and published in the New England
Journal of Medicine in June 2015 [25,27]. Idarucizumab was subsequently approved as Praxbind by the FDA in October 2015 and by the
European Medicines Agency in November 2015 [28,29].
All patients in RE-VERSE AD receive 5 g idarucizumab administered
as 2 successive intravenous infusions of 2.5-g vials, each given as a rapid
infusion, no more than 15 minutes apart [25]. The only requirement for
care between the 2 infusions is a blood draw for coagulation analysis;
this would not be considered a necessary step in clinical practice. The
primary end point is the maximum percentage reversal of the anticoagulant effect of dabigatran within 4 hours of completion of idarucizumab
dosing, as assessed by central laboratory measurement of the dTT or
ECT. Key clinical end points include time to cessation of bleeding in
group A patients and assessment of hemostasis during interventions
in group B patients. An interim analysis of the ﬁrst 90 patients enrolled
(51 in group A, 39 in group B) revealed that most (N90%) were receiving
dabigatran for stroke prevention in the setting of NVAF and, accordingly,
were elderly (median age: 76.5 years) and had a typical ageappropriate
comorbidity burden, including some degree of renal insufﬁciency.
In keeping with the “all-comers” approach to establishing eligibility
for idarucizumab to reverse dabigatran-associated anticoagulation, 16
of the 51 group A patients were hemodynamically unstable at enrollment, and 18 had intracranial hemorrhage. In group B, the most common indications for emergency surgery were open bone fractures and
acute abdomen. The median patient-reported time since the last dose
of dabigatran was 15.2 and 16.6 hours in groups A and B, respectively,
although this time included initial evaluation after arrival at the site of
care [25].
Overall, 68 (76%) and 81 (90%) of the 90 patients had an elevated
dTT or ECT at study entry as determined by central laboratory analysis.
Normal dTTs were found in 11 of 51 patients in group A and in 11 of 39
patients in group B, and normal ECTs in 4 and 5 patients in the respective groups. It should be kept in mind that treating clinicians did not
have access to these results in “real time” and that all enrollment criteria
were clinical, based on a bedside evaluation that immediate reversal
was warranted [25].
The efﬁcacy analysis included only those patients with elevated
clotting test results at baseline. After administration of 5-g
idarucizumab, the median maximum percentage reversal in dTT or
ECT within 4 hours in eligible patients was 100% (95% conﬁdence interval, 100%-100%), and reversal was evident immediately after the ﬁrst
vial of idarucizumab was given. Idarucizumab normalized dTT in 98%
(group A) and 93% (group B) and ECT in 89% (group A) and 88%
(group B) of eligible patients (Fig. 1) [25].
Plasma concentrations of unbound dabigatran were reduced to at or
near the lower limit of quantiﬁcation in all but 1 patient immediately
after idarucizumab administration. At 24 hours, 79% of patients
had plasma concentrations of active (unbound) dabigatran that were
b20 ng/mL, a level associated with little or no anticoagulant activity [9].
The subsequent increases in dabigatran concentrations observed in 6
and 16 patients, at 12 and 24 hours after idarucizumab administration,
respectively, were accompanied by increases in clotting times. This response is most likely attributable to the redistribution of extravascular
dabigatran into the intravascular compartment. If these elevations in
clotting tests are associated with rebleeding, a second 5-g dose of
idarucizumab may be considered in such patients, although the safety
and effectiveness of a second dose has yet to be established [16].
In the 51 patients in group A, time to bleeding cessation could be determined in 38 patients (13 patients had bleeding at sites not readily accessible). The investigator-reported median time to cessation of
bleeding was 11.4 hours, but this information is highly variable and
was not guided by any speciﬁc evaluation schedule or deﬁnition. In
group B, normal intraoperative hemostasis was reported in 92% of the
36 patients who underwent procedures after reversal [25]. The median
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Fig. 1. Time course of the dilute thrombin time and ecarin clotting time before and after the administration of idarucizumab. Reprinted with permission of Massachusetts Medical Society
from Pollack et al. [25] The analyses included 51 patients who had serious bleeding (group A; A and C) and 39 who required urgent surgery or intervention (group B; B and D).
Idarucizumab was administered in 2 infusions. Blood samples were obtained at baseline, after the ﬁrst infusion, at 10-30 minutes after the administration of the second infusion, and
at 1, 2, 4, 12, and 24 hours. Data are presented as box-and-whisker plots, in which the top and bottom of the rectangles indicate the 75th and 25th percentiles, respectively; the
horizontal lines within the rectangles indicate the 50th percentile; the lines above and below the rectangles indicate the 90th and 10th percentiles, respectively; and the dots above
and below the lines indicate the 95th and 5th percentiles, respectively. The dashed lines indicate the upper limit of the normal range for the tests.

time between administration of idarucizumab and the start of the procedure was 1.7 hours, and no postsurgical bleeding complications
were reported in the 24 hours after surgery for any of the 36 procedural
patients [30].

Thromboembolic events (including deep vein thrombosis, pulmonary embolism, myocardial infarction, or ischemic stroke) occurred in
5 of the 90 patients in the interim analysis: 1 occurring within 48
hours of idarucizumab administration, and 4 more than 72 hours after

C.V. Pollack Jr / American Journal of Emergency Medicine 34 (2016) 33–38

dosing. It is signiﬁcant that at the time of the complication, none of these
5 patients had been re-initiated on any antithrombotic therapy after reversal of anticoagulation. Among these 90 patients, 18 (9 in each group)
died during the 90-day follow-up period. The 9 deaths that occurred
within 96 hours after reversal reﬂected the disease process or injury
that prompted the need for reversal, whereas the 9 deaths that occurred
later were related to pre-existing medical conditions. No deaths and no
serious adverse events were attributable to idarucizumab [25].
Most patients had anticoagulation therapy re-initiated after reversal [25]. The time to restart varied, with a longer time for patients in group A who had experienced life-threatening bleeding
events than for surgical patients in group B for whom hemostasis
was more clearly established before re-initiation (median time:
4.1 vs 1.4 days, respectively) [31]. Approximately half of the patients who restarted on dabigatran were given an injectable anticoagulant ﬁrst [31]. In patients with renal impairment, the half-lives
of both dabigatran and idarucizumab are prolonged [1,16]. No adjustment of timing of re-initiation of dabigatran is necessary in
these patients.
The interim results supported the rapid approval of idarucizumab by
both the FDA and the European Medicines Agency. The target population
mirrored the inclusion criteria and administration used in RE-VERSE AD.
The study will be complete in 2016 after the enrollment of 500 patients
worldwide [25]. Clinical use of idarucizumab will ensue in parallel to
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study enrollment, and there will doubtless be varying protocols governing
access to the reversal agent in the emergency care setting.
2. Conclusions
Use of idarucizumab will be unusual in the clinical setting if it is used
per label and as it is being used in RE-VERSE AD: only in those situations
in which emergency reversal is clinically warranted. Most DOAC-related
bleeding does not require reversal; most invasive procedures in
anticoagulated patients can be safely delayed until the anticoagulant effect has diminished. The exceptions–true surgical emergencies, intracranial hemorrhage, exsanguinating gastrointestinal bleeds, multiple
trauma with hemorrhagic shock–are dramatic but rare. The usual measures to support and stabilize dabigatran-treated patients with controllable hemorrhage of bleeding concerns should still be followed,
reserving idarucizumab for refractory cases (Fig. 2).
Further clinical experience will be required to determine the frequency of a need for repeated doses of idarucizumab. Given the overwhelming nature of the 5-g dose (with respect to dabigatran levels
measured in the Randomized Evaluation of Long-term anticoagulation
therapY [RE-LY] trial), this should be unusual and should be considered
only when pathologic bleeding persists or recurs after initial reversal, or
if a second urgent/emergent procedure is required and clotting studies
suggest a recurrent dabigatran effect. It is anticipated that there will

Fig. 2. Management of bleeding in patients taking direct oral anticoagulants (DOACs). Possible therapeutic measures in case of minor or severe bleeding in patients on DOAC therapy. Based
on van Ryn et al. [8] Adapted with permission of Oxford University Press from Heidbuchel et al. [5] aPCC = activated prothrombin complex concentrate; IV = intravenous; NOAC = novel
oral anticoagulant; PCC = prothrombin complex concentrate; RBC = red blood cell count; WBC = white blood cell count.
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be broad and deep interest in the clinical use of the drug and the outcomes achieved.
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